公开(公告)号：US20090270433A1

公开(公告)日：2009-10-29

申请号：US12234116

申请日：2008-09-19

Applicant: Richard Clark ,  Atsushi Takemura ,  Nobuhisa Watanabe ,  Osamu Asano ,  Tadashi Nagakura ,  Kimlyo Tabata

Inventor： Richard Clark ,  Atsushi Takemura ,  Nobuhisa Watanabe ,  Osamu Asano ,  Tadashi Nagakura ,  Kimlyo Tabata

IPC: A61K31/506 ,  C07D413/14 ,  C07D405/14 ,  A61K31/427

CPC classification number: C07D417/14 ,  C07D209/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

Abstract: A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein R1 represents hydrogen, R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc.]

Abstract translation: 由以下通式（1）表示的化合物或其盐具有丝氨酸蛋白酶抑制活性，对凝血因子VIIa特别优异的抑制活性。 该化合物或其盐可用作与血栓形成相关的疾病的治疗和/或预防剂。 [其中R 1表示氢，R 2表示任选取代的苯基等，R 3表示任选取代的C 6-10芳基等]

公开(公告)号：US20090203911A1

公开(公告)日：2009-08-13

申请号：US12189590

申请日：2008-08-11

Applicant: Shuhei MIYAZAWA ,  Masanobu Shinoda ,  Tetsuya Kawahara ,  Nobuhisa Watanabe ,  Hitoshi Harada ,  Daisuke Iida ,  Hiroki Terauchi ,  Junichi Nagakawa ,  Hideaki Fujisaki ,  Atsuhiko Kubota ,  Masato Ueda

Inventor： Shuhei MIYAZAWA ,  Masanobu Shinoda ,  Tetsuya Kawahara ,  Nobuhisa Watanabe ,  Hitoshi Harada ,  Daisuke Iida ,  Hiroki Terauchi ,  Junichi Nagakawa ,  Hideaki Fujisaki ,  Atsuhiko Kubota ,  Masato Ueda

IPC: C07D405/14 ,  C07D401/12

CPC classification number: C07D491/04 ,  C07D405/14 ,  C07D493/08 ,  C07D493/10

Abstract: A novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases is provided, which has an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

Abstract translation: 提供了可用作酸性相关疾病的治疗或预防剂的新型化合物，其对胃酸分泌具有优异的抑制作用，保持对胃酸分泌的抑制作用的优异效果，从而保持胃内pH高 长时间，具有更多的安全性和适当的物理化学稳定性。 提供一种化合物，其中R 1和R 3可以相同或不同，各自表示氢原子或C 1 -C 6烷基; R2代表（5,5-二甲基-1,3-二恶烷-2-基）甲氧基，5,7-二氧杂螺[2.5]辛-6-基甲氧基，1,5,9-三氧杂螺[5.5]十一烷-3 - 甲氧基或（2,2-二甲基-1,3-二恶烷-5-基）甲氧基; R4，R5，R6和R7表示氢原子，卤素原子，C1-C6烷基，C1-C6卤代烷基，C1-C6烷氧基或C1-C6卤代烷氧基; W1表示单键，亚甲基或亚乙基，它们的盐或它们的溶剂合物。

公开(公告)号：US20090182149A1

公开(公告)日：2009-07-16

申请号：US12296902

申请日：2006-10-13

Applicant: Tetsuya Kawahara ,  Hitoshi Harada ,  Hiroki Terauchi ,  Nobuhisa Watanabe ,  Masato Ueda ,  Atsushi Kamada ,  Sachiko Kikuchi ,  Hiroshi Ishihara ,  Koichi Koyama

Inventor： Tetsuya Kawahara ,  Hitoshi Harada ,  Hiroki Terauchi ,  Nobuhisa Watanabe ,  Masato Ueda ,  Atsushi Kamada ,  Sachiko Kikuchi ,  Hiroshi Ishihara ,  Koichi Koyama

IPC: C07D405/14

CPC classification number: C07D405/14

Abstract: Salts of 2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole and their crystalline and amorphous forms.

Abstract translation: 2 - [（{4 - [（2,2-二甲基-1,3-二恶烷-5-基）甲氧基] -3,5-二甲基吡啶-2-基}甲基）亚磺酰基] -1H-苯并咪唑的盐及其 晶体和无定形形式。

公开(公告)号：US07317538B2

公开(公告)日：2008-01-08

申请号：US11028610

申请日：2005-01-05

Applicant: Hideo Wada ,  Nobuhisa Watanabe ,  Takayuki Taminaga

Inventor： Hideo Wada ,  Nobuhisa Watanabe ,  Takayuki Taminaga

IPC: G01B11/14

CPC classification number: G01P3/366 ,  G01S17/58

Abstract: In an optical movement information detector, light emitted from a laser diode (1) is split into a first beam (10), a second beam (11) and a third beam (12) by beam splitters (2a, 2b). The first, second and third beams are converged by a condenser lens (4) upon a surface of an object to be measured (5) to form a beam spot (13) thereon. Diffused light from the beam spot (13) is received by a photodiode (6) and an output signal of the photodiode (6) is processed by a signal processing circuit (20) including an analog-digital converter (8) and a Fourier transforming unit (9). A detecting section (21) obtains, for example, a moving velocity and a moving direction of the object based on spectrum peak frequencies obtained by the Fourier transform.

Abstract translation: 在光学运动信息检测器中，从激光二极管（1）发射的光通过分束器（2a，2b）分成第一光束（10），第二光束（11）和第三光束（12）。 第一，第二和第三光束由聚光透镜（4）会聚在待测物体（5）的表面上，以在其上形成光斑（13）。 来自光束点（13）的漫射光由光电二极管（6）接收，并且光电二极管（6）的输出信号由包括模数转换器（8）的信号处理电路（20）和傅立叶变换 单位（9）。 检测部（21）基于通过傅里叶变换获得的频谱峰值频率，获得例如物体的移动速度和移动方向。

公开(公告)号：US06916837B2

公开(公告)日：2005-07-12

申请号：US10294198

申请日：2002-11-14

Applicant: Takashi Satoh ,  Yasushi Okamoto ,  Osamu Asano ,  Nobuhisa Watanabe ,  Tadashi Nagakura ,  Takao Saeki ,  Atsushi Inoue ,  Masahiro Sakurai

Inventor： Takashi Satoh ,  Yasushi Okamoto ,  Osamu Asano ,  Nobuhisa Watanabe ,  Tadashi Nagakura ,  Takao Saeki ,  Atsushi Inoue ,  Masahiro Sakurai

IPC: A61K31/192 ,  A61K31/194 ,  A61K31/36 ,  A61K31/381 ,  A61K31/4164 ,  A61K31/472 ,  A61K31/606 ,  A61P7/02 ,  A61P43/00 ,  C07C257/18 ,  C07C275/42 ,  C07C311/08 ,  C07C311/21 ,  C07C311/29 ,  C07C311/46 ,  C07C317/14 ,  C07C317/32 ,  C07D217/06 ,  C07D217/22 ,  C07D233/84 ,  C07D317/68 ,  C07D333/22 ,  C07D333/28 ,  C07D333/34 ,  C07D333/38 ,  C07D333/40 ,  C07D333/62 ,  C40B40/04 ,  A61K31/415 ,  A61K31/21 ,  A61K31/24 ,  A61K31/38

CPC classification number: C07D333/62 ,  C07C257/18 ,  C07C275/42 ,  C07C311/08 ,  C07C311/21 ,  C07C311/29 ,  C07C311/46 ,  C07C317/14 ,  C07D217/22 ,  C07D233/84 ,  C07D333/22 ,  C07D333/28 ,  C07D333/34 ,  C07D333/38 ,  C07D333/40

Abstract: Amidino derivatives represented by the following general formula (I): {where X is a group represented by R1SO2NR2— (wherein R1 represents optionally substituted C6-14 aryl, etc. and R2 represents hydrogen atom, etc.), etc., Ar1 represents 2,6-naphthylene, etc., R3 represents hydrogen atom, etc. and Y represents carboxyphenyl, etc.} and their pharmacologically acceptable salts or solvates.

Abstract translation: 由以下通式（I）表示的脒基衍生物：其中X是由R 1表示的基团SO 2 - （其中 R 1表示任选取代的C 6-14芳基等，R 2表示氢原子等）等，Ar 1， SUP> 1表示2,6-亚萘基等，R 3表示氢原子等，Y表示羧基苯基等}及其药理学上可接受的盐或溶剂化物。

公开(公告)号：US20050146707A1

公开(公告)日：2005-07-07

申请号：US11028610

申请日：2005-01-05

Applicant: Hideo Wada ,  Nobuhisa Watanabe ,  Takayuki Taminaga

Inventor： Hideo Wada ,  Nobuhisa Watanabe ,  Takayuki Taminaga

IPC: G01S7/48 ,  G01B11/00 ,  G01P3/36 ,  G01S17/02 ,  G01S17/58

CPC classification number: G01P3/366 ,  G01S17/58

Abstract: In an optical movement information detector, light emitted from a laser diode (1) is split into a first beam (10), a second beam (11) and a third beam (12) by beam splitters (2a, 2b). The first, second and third beams are converged by a condenser lens (4) upon a surface of an object to be measured (5) to form a beam spot (13) thereon. Diffused light from the beam spot (13) is received by a photodiode (6) and an output signal of the photodiode (6) is processed by a signal processing circuit (20) including an analog-digital converter (8) and a Fourier transforming unit (9). A detecting section (21) obtains, for example, a moving velocity and a moving direction of the object based on spectrum peak frequencies obtained by the Fourier transform.

Abstract translation: 在光学运动信息检测器中，从激光二极管（1）发射的光通过分束器（2a，2b）分成第一光束（10），第二光束（11）和第三光束（12）。 第一，第二和第三光束由聚光透镜（4）会聚在待测物体（5）的表面上，以在其上形成光斑（13）。 来自光束点（13）的漫射光由光电二极管（6）接收，并且光电二极管（6）的输出信号由包括模数转换器（8）的信号处理电路（20）和傅立叶变换 单位（9）。 检测部（21）基于通过傅里叶变换获得的频谱峰值频率，获得例如物体的移动速度和移动方向。

公开(公告)号：US06841549B1

公开(公告)日：2005-01-11

申请号：US10018688

申请日：2000-06-30

Applicant: Osamu Asano ,  Hitoshi Harada ,  Seiji Yoshikawa ,  Nobuhisa Watanabe ,  Takashi Inoue ,  Tatsuo Horizoe ,  Nobuyuki Yasuda ,  Kaya Ohashi ,  Hiroe Minami ,  Junsaku Nagaoka ,  Manabu Murakami ,  Seiichi Kobayashi ,  Isao Tanaka ,  Tsutomu Kawata ,  Naoyuki Shimomura ,  Hiroshi Akamatsu ,  Naoki Ozeki ,  Toshikazu Shimizu ,  Kenji Hayashi ,  Toyokazu Haga ,  Shigeto Negi ,  Toshihiko Naito

Inventor： Osamu Asano ,  Hitoshi Harada ,  Seiji Yoshikawa ,  Nobuhisa Watanabe ,  Takashi Inoue ,  Tatsuo Horizoe ,  Nobuyuki Yasuda ,  Kaya Ohashi ,  Hiroe Minami ,  Junsaku Nagaoka ,  Manabu Murakami ,  Seiichi Kobayashi ,  Isao Tanaka ,  Tsutomu Kawata ,  Naoyuki Shimomura ,  Hiroshi Akamatsu ,  Naoki Ozeki ,  Toshikazu Shimizu ,  Kenji Hayashi ,  Toyokazu Haga ,  Shigeto Negi ,  Toshihiko Naito

IPC: A61P3/10 ,  A61P43/00 ,  C07D471/04 ,  C07D473/00 ,  C07D473/34 ,  C07D473/40 ,  A16K31/33 ,  C07D239/70 ,  C07D471/00 ,  C07D487/00 ,  A16K31/52

CPC classification number: C07D471/04 ,  C07D473/00 ,  C07D473/34 ,  C07D473/40

Abstract: The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action.That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I); (wherein R1 represents e.g. an amino group which may be substituted with an alkyl group; R2 represents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; R3 represents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.

Abstract translation: 本发明提供了一种基于腺苷A2受体拮抗剂作用的新型糖尿病和糖尿病并发症的预防或治疗剂。即提供了具有腺苷A2受体拮抗剂作用的新颖的缩合咪唑化合物，是 有效预防或治疗糖尿病和糖尿病并发症，并由式（I）表示;（其中R 1表示例如可被烷基取代的氨基; R 2表示例如氢原子， 可以被羟基取代的烷基，环烷基或烷基，烯基或炔基; R 3表示例如任选取代的烷基，烯基，炔基，芳基，杂芳基， 吡啶酮基，嘧啶酮基或哌嗪酮基; Ar表示例如任选取代的芳基或杂芳基; Q和W彼此相同或不同，每个代表 N或CH），其药理学上可接受的盐或其水合物。

公开(公告)号：US06568580B2

公开(公告)日：2003-05-27

申请号：US09911802

申请日：2001-07-25

Applicant: Shoriki Narita ,  Makoto Imanishi ,  Takaharu Mae ,  Shinji Kanayama ,  Nobuhisa Watanabe

Inventor： Shoriki Narita ,  Makoto Imanishi ,  Takaharu Mae ,  Shinji Kanayama ,  Nobuhisa Watanabe

IPC: B23K3704

CPC classification number: H01L24/78 ,  H01L21/67138 ,  H01L21/681 ,  H01L24/11 ,  H01L2224/05568 ,  H01L2224/05573 ,  H01L2224/1134 ,  H01L2224/78268 ,  H01L2224/78301 ,  H01L2224/786 ,  H01L2224/85045 ,  H01L2224/851 ,  H01L2224/85205 ,  H01L2924/00013 ,  H01L2924/00014 ,  H01L2924/01006 ,  H01L2924/01033 ,  H01L2924/01039 ,  H01L2924/01057 ,  H01L2924/01061 ,  H01L2924/14 ,  Y10T29/53178 ,  H01L2224/13099 ,  H01L2224/48 ,  H01L2224/45099 ,  H01L2224/05599

Abstract: Wafers are previously positioned so that the wafer orientation flat is oriented in a particular direction. A transporting means then moves and places the previously positioned wafer on a bonding stage where bumps are formed on the wafer by means of a bonding head. The transporting means has a sensor for detecting the position of the orientation flat of a wafer on the bonding stage from a position above the bonding stage, thereby avoiding the adverse effects of heat from the bonding stage during orientation flat detection.

公开(公告)号：US5801180A

公开(公告)日：1998-09-01

申请号：US904260

申请日：1997-07-31

Applicant: Yasutaka Takase ,  Nobuhisa Watanabe ,  Makoto Matsui ,  Hironori Ikuta ,  Teiji Kimura ,  Takao Saeki ,  Hideyuki Adachi ,  Tadakazu Tokumura ,  Hisatoshi Mochida ,  Yasunori Akita ,  Shigeru Souda

Inventor： Yasutaka Takase ,  Nobuhisa Watanabe ,  Makoto Matsui ,  Hironori Ikuta ,  Teiji Kimura ,  Takao Saeki ,  Hideyuki Adachi ,  Tadakazu Tokumura ,  Hisatoshi Mochida ,  Yasunori Akita ,  Shigeru Souda

IPC: C07D215/42 ,  A61K31/415 ,  A61K31/4184 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/505 ,  A61K31/517 ,  A61K31/519 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P37/00 ,  A61P43/00 ,  B60S1/16 ,  B60S1/24 ,  C07D215/48 ,  C07D235/06 ,  C07D235/08 ,  C07D239/78 ,  C07D239/84 ,  C07D239/86 ,  C07D239/88 ,  C07D239/90 ,  C07D239/94 ,  C07D239/95 ,  C07D239/96 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D471/04 ,  C07D491/04 ,  C07D491/056 ,  C07D521/00 ,  F16C7/02 ,  F16C11/04

CPC classification number: C07D235/06 ,  C07D215/42 ,  C07D231/12 ,  C07D233/56 ,  C07D239/84 ,  C07D239/86 ,  C07D239/88 ,  C07D239/94 ,  C07D239/95 ,  C07D239/96 ,  C07D249/08 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/10 ,  C07D413/12 ,  C07D471/04 ,  C07D491/04

Abstract: The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof which is useful for various ischemic heart diseases and the like: ##STR1## �in formula (1), ring A represents a benzene ring, a pyridine ring or a cyclohexane ring; ring B represents a pyridine ring, a pyrimidine ring or an imidazole ring, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent each a hydrogen atom, a halogen atom or a group such as a lower alkoxy group; R.sup.5 represents a group represented by the formula --NR.sup.11 R.sup.12 (wherein R.sup.11 and R.sup.12 represent each a hydrogen atom or a group such as a lower alkyl group) or the like; and R.sup.6 represents a group represented by the formula ##STR2## (wherein R.sup.19 represents a hydrogen atom, a lower alkyl group or the like; R.sup.20, R.sup.21 and R.sup.22 represent each a hydrogen atom, a halogen atom, a hydroxyl group or the like; and r represents 0 or an integer of 1 to 8)!.

Abstract translation: 本发明提供由以下通式（1）表示的含氮杂环化合物或其药理学上可接受的盐，其可用于各种缺血性心脏病等：（1）[式（1）中，环A 表示苯环，吡啶环或环己烷环; 环B表示吡啶环，嘧啶环或咪唑环，R1，R2，R3和R4分别表示氢原子，卤素原子或低级烷氧基等基团。 R5表示由式-NR11R12表示的基团（其中R11和R12各自表示氢原子或低级烷基等基团）等; R 6表示氢原子，低级烷基等，R 20，R 21，R 22分别表示氢原子，卤素原子，羟基等。 和r表示0或1〜8的整数）]。

公开(公告)号：US5707998A

公开(公告)日：1998-01-13

申请号：US525739

申请日：1995-09-25

Applicant: Yasutaka Takase ,  Nobuhisa Watanabe ,  Hideyuki Adachi ,  Kohtaro Kodama ,  Hiroki Ishihara ,  Takao Saeki ,  Shigeru Souda

Inventor： Yasutaka Takase ,  Nobuhisa Watanabe ,  Hideyuki Adachi ,  Kohtaro Kodama ,  Hiroki Ishihara ,  Takao Saeki ,  Shigeru Souda

IPC: C07D405/12 ,  C07D405/14 ,  C07D521/00 ,  C07D403/00 ,  A61K31/505 ,  C07D239/94 ,  C07D403/02

CPC classification number: C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/12 ,  C07D405/14

Abstract: The present invention relates to a nitrogen-containing heterocyclic compound exhibiting an inhibitory activity against cGMP-PDE. The compound represented by the formula (I) or a pharmacologically acceptable salt thereof: ##STR1## wherein R.sup.1 represents a group represented by the formula: --NR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 each represent hydrogen, lower alkyl or the like) or the like; R.sup.2 represents a group represented by the formula: ##STR2## (wherein R.sup.8 represents a carboxyl group which may be protected, or the like) or the like; and R.sup.3 represents a group represented by the formula: ##STR3## (wherein R.sup.6 and R.sup.7 each represent hydrogen, lower alkyl or the like) or the like.

Abstract translation: PCT No.PCT / JP94 / 00446 Sec。 371 1995年9月25日第 102（e）1995年9月25日PCT PCT 1994年3月18日PCT公布。 公开号WO94 / 22855 日期：1994年10月13日本发明涉及对cGMP-PDE具有抑制活性的含氮杂环化合物。 由式（I）表示的化合物或其药学上可接受的盐：其中R1表示由式-NR4R5表示的基团（其中R4和R5各自表示氢，低级烷基等）或 类似; R2表示由下式表示的基团：其中R8表示可被保护的羧基等）等。 并且R 3表示由下式表示的基团：其中R 6和R 7各自表示氢，低级烷基等）等。